NCT01263548View on ClinicalTrials.gov

To Evaluate the Safety and Metabolic Profile of Vyvanse for the Treatment of ADHD in Euthymic Adults With Bipolar I/II Disorder

CompletedOBSERVATIONAL
Enrollment

45

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Attention Deficit/Hyperactivity DisorderBipolar Disorder
Interventions
DRUG

lisdexamfetamine dimesylate

Dosage form: Capsules; Dosage strength: 30-70mg/day, flexible dosing; Duration: 4 weeks

Trial Locations (1)

M5T 2S8

Mood Disorders Psychopharmacology Unit, Toronto

Sponsors

Collaborators (1)

Shire
All Listed Sponsors
collaborator

Shire

INDUSTRY

lead

University Health Network, Toronto

OTHER

NCT01263548 - To Evaluate the Safety and Metabolic Profile of Vyvanse for the Treatment of ADHD in Euthymic Adults With Bipolar I/II Disorder | Biotech Hunter | Biotech Hunter